Statement 7 Dec 2022

Call for special pathogen sharing measures to be included in COP15 Digital Sequence Information negotiations

IFPMA statement on behalf of the pharmaceutical industry at the Convention on Biological Diversity (CBD) COP 15 meeting regarding Digital Sequence Information.

Statement 7 Dec 2022

Pharma industry contributions to third meeting of the Intergovernmental Negotiating Body (INB)

During the World Health Organization (WHO) Third Meeting of the Intergovernmental Negotiating Body, IFPMA delivered four messages.

Infographic 5 Dec 2022

Impact of a waiver of intellectual property rights for COVID-19 therapeutics

As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.

Press release 30 Nov 2022

Survey shows an improvement in research-based pharmaceutical industry reputation with people valuing pharma innovation and the benefits it brings to society

New annual research conducted by Ipsos UK, shows that the research-based pharmaceutical industry has garnered a positive reputation, with its pandemic response and the impact of its innovations seen as key strengths by the general public.

Statement 30 Nov 2022

Proposals from the pharmaceutical industry for the G7 Hiroshima Summit Health Agenda

The Japanese Pharmaceutical Manufacturers Association (JPMA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) jointly submitted the “Proposals from the Pharmaceutical Industry for the G7 Hiroshima Summit Health Agenda” to the Prime Minister, Minister of Health, Labor and Welfare, Minister of Finance, and Minister of Foreign Affairs.

Expert insight 24 Nov 2022

Rebuilding momentum on antibiotics research, giving innovators a chance to pull through

The pace of resistance to existing antibiotics is outpacing the rate at which new ones can reach the market and be used against difficult-to-treat infections.

Position paper 23 Nov 2022

Pathogen sharing and global health security

Responding to the impact of the Nagoya Protocol on Access and Benefit Sharing

Expert insight 15 Nov 2022

Renewing industry’s commitment to better access to diabetes care on World Diabetes Day

This World Diabetes Day (WDD), IFPMA and its members are renewing our commitment to take proactive steps to improve access to diabetes care and make progress toward the achievement of SDG target 3.4.

Statement 28 Oct 2022

IFPMA Response to the Release of the ACT-A Evaluation Report

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) was a founding member of ACT-A when it was launched in April 2020. We welcomed the vision of the ACT-A to involve the private sector, including the innovative pharmaceutical industry, to join this unique global collaboration set up to accelerate development, production, and equitable access to...

Statement 27 Oct 2022

IFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Items recommended by the World Health Assembly and the Executive Board

IFPMA welcomes the opportunity to make this statement and to share our Covid-19 Lessons Learned, which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility must be preserved to ensure our collective ability to fight against unknown diseases.

Statement 27 Oct 2022

IFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Noncommunicable disease prevention and control

IFPMA appreciates the opportunity to make this statement. The ongoing fight against COVID-19 has shown that those with chronic conditions and co-morbidities are often the most vulnerable and have suffered the most throughout the pandemic.

Position paper 25 Oct 2022

Principles for a fit-for-purpose global health architecture

Biopharmaceutical industry’s considerations on key elements for an effective multilateral Pandemic Prevention, Preparedness, and Response (PPR) instrument.